Abstract
Get full access to this article
View all access options for this article.
References
1.
Bousquet
J
Khaltaev
N
Cruz
A
. Allergic rhinitis and its impact on asthma (ARIA) 2008 . Allergy . 2008 ;63 (suppl 86 ):8 -160 .
2.
Wallace
DV
Dykewicz
MS
. The diagnosis and management of rhinitis: an updated practice parameter . J Allergy Clin Immunol . 2008 ;122 :S1 -S84 .
3.FDA news release. FDA approves new treatment for allergies . October
23 , 2006 .
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108773.htm
. Accessed October 9, 2009 .
4.
Stoeck
M
Riedel
R
Hochaus
G
. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide . J Pharmacol Exp Ther . 2004 ;309 (1 ):249 -258 .
5.
Dhillon
S
Wagstaff
AJ
. Ciclesonide nasal spray in allergic rhinitis . Drugs . 2208 ;68 (6 ):875 -883 .
6.
Chapman
KR
Patel
P
D’Urzo
AD
. Maintenance of asthma control by once-daily ciclesonide in adults with persistent asthma . Allergy . 2005 ;60 :330 -337 .
7.Ciclesonide (Omnaris™) nasal spray [package insert] . November
2007 . Marlborough, MA : Sepracor Inc .
8.
Rohatagi
S
Arya
V
Zech
K
. Population pharmacokinetics and pharmacodynamics of ciclesonide . J Clin Pharmacol . 2003 ;43 (4 ):365 -378 .
9.How to use Omnaris nasal spray .
www.omnaris.com/aboutOmnaris/how-to-use-omnaris.html
. Accessed October 9, 2009 .